Q3 2023 13F Holders as of 30 Sep 2023
-
Type / Class
-
Equity / Common Shares, no par value
-
Shares outstanding
-
31,523,534
-
Total 13F shares
-
1,180,449
-
Share change
-
-43,891
-
Total reported value
-
$2,160,639
-
Put/Call ratio
-
6.6%
-
Price per share
-
$1.83
-
Number of holders
-
16
-
Value change
-
-$88,601
-
Number of buys
-
4
-
Number of sells
-
6
Institutional Holders of ImmunoPrecise Antibodies Ltd. - Common Shares, no par value (IPA) as of Q3 2023
As of 30 Sep 2023,
ImmunoPrecise Antibodies Ltd. - Common Shares, no par value (IPA) was held by
16 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
1,180,449 shares.
The largest 10 holders included
INGALLS & SNYDER LLC, CIBC WORLD MARKET INC., Gradient Capital Advisors, LLC, GEODE CAPITAL MANAGEMENT, LLC, DIMENSIONAL FUND ADVISORS LP, Federation des caisses Desjardins du Quebec, RENAISSANCE TECHNOLOGIES LLC, Rathbones Group PLC, CITADEL ADVISORS LLC, and Royal Bank of Canada.
This page lists
16
institutional shareholders reporting positions in this security
for the Q3 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.